Table 1:

Participant Characteristics

	Healthy Control	Methamphetamine Use Disorder	Group Difference
Demographics
Age (years)	34.9 ± 6.9	36.0 ± 7.5	U = 4249.5, z = 0.842, p = 0.400
Women/Men	34/55	34/55	None
Education (years)	13.3 ± 1.8	12.4 ± 2.0	U = 2800.5, z = −3.483, p < 0.001*
Employed	53	15	X2 (1) = 36.032, p < 0.001*
Ethnicity/Race			X2 (4) = 26.256, p < 0.001*
African American	22	6	+
Asian/Pacific Islander	6	5	−
Caucasian	44	31	+
Hispanic	12	27	+
Other	5	20	+
Any Use in Past 30 Days
Alcohol	57	58	X2 (1) = 0.069, p = 0.792
Tobacco (cigarettes)	73	73	None
Cannabis	26	38	X2 (1) = 3.513, p = 0.061
Methamphetamine Use
Age of first use		23.2 ± 7.8#
Lifetime years		9.8 ± 6.6#
Days in the past 30		16.1 ± 10.7†
Preferred route of administration F
Smoking		57
Intravenous		18
Intranasal		11
Oral		1
None		1
At Brain Scan
Days abstinent		22.1 ± 25.6†
Craving		21.4 ± 26.2#
BDI	3.1 ± 5.5	8.7 ± 8.6#	U = 4993.0, z = 5.851, p < 0.001*
Scanner			Χ2 (2) = 29.469, p < 0.001*
1.5-T Sonata	23	18	–
3-T Trio	9	41	+
3-T Prisma	57	30	+

Values of variables are the number of participants in the relevant group or group M ± SD. Craving for methamphetamine was measured on a visual analog scale from 0 (none) to 100 (extreme). The Beck Depression Inventory (BDI) distinguishes no or minimal (< 10), mild to moderate (10–18), moderate to severe (19–29), and severe depressive symptoms (30–63).⁶¹ U (Mann-Whitney U test), X² (Pearson’s chi-square test),

^*significant group difference at p < 0.05, significant (+) or non-significant (−) at p < 0.05 in Bonferroni-adjusted post hoc analyses

^†significantly or

^#non-significantly different at p < 0.05 across scanners in Kruskal-Wallis tests (specific p-values given in text)

^Fnon-significantly different across scanners in Fisher’s exact test (X² (8) = 3.526, p = 0.981)